21.54
price up icon0.28%   0.06
after-market After Hours: 21.54
loading
Cidara Therapeutics Inc stock is traded at $21.54, with a volume of 50,806. It is up +0.28% in the last 24 hours and down -2.22% over the past month. Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$21.48
Open:
$21.37
24h Volume:
50,806
Relative Volume:
0.38
Market Cap:
$226.57M
Revenue:
$56.54M
Net Income/Loss:
$-30.70M
P/E Ratio:
-55.23
EPS:
-0.39
Net Cash Flow:
$-31.05M
1W Performance:
+10.80%
1M Performance:
-2.22%
6M Performance:
+70.95%
1Y Performance:
+65.69%
1-Day Range:
Value
$20.95
$22.06
1-Week Range:
Value
$19.18
$22.82
52-Week Range:
Value
$10.14
$28.42

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name
Name
Cidara Therapeutics Inc
Name
Phone
858-752-6170
Name
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Name
Employee
73
Name
Twitter
@CidaraThera
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
CDTX's Discussions on Twitter

Compare CDTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CDTX
Cidara Therapeutics Inc
21.54 226.57M 56.54M -30.70M -31.05M -0.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-25 Initiated Citizens JMP Mkt Outperform
Jan-27-25 Resumed Cantor Fitzgerald Overweight
Dec-13-24 Initiated RBC Capital Mkts Outperform
Nov-08-24 Initiated Guggenheim Buy
Aug-14-24 Upgrade H.C. Wainwright Neutral → Buy
Dec-03-21 Resumed H.C. Wainwright Buy
Sep-22-21 Upgrade WBB Securities Buy → Strong Buy
Mar-04-21 Initiated Aegis Capital Buy
Sep-04-19 Upgrade Wedbush Neutral → Outperform
Jul-26-18 Initiated Citigroup Buy
Apr-21-17 Initiated Raymond James Strong Buy
Apr-17-17 Reiterated H.C. Wainwright Buy
Apr-12-17 Initiated Ladenburg Thalmann Buy
Apr-11-17 Resumed Wedbush Outperform
Feb-22-17 Reiterated H.C. Wainwright Buy
Feb-22-17 Upgrade WBB Securities Sell → Hold
Dec-21-16 Resumed Leerink Partners Outperform
Dec-19-16 Initiated H.C. Wainwright Buy
Sep-23-16 Downgrade WBB Securities Hold → Sell
Oct-09-15 Upgrade WBB Securities Sell → Hold
May-11-15 Initiated Jefferies Buy
May-11-15 Initiated Leerink Partners Outperform
May-11-15 Initiated Needham Buy
May-11-15 Initiated Wedbush Outperform
Apr-23-15 Initiated WBB Securities Sell
View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

pulisher
Apr 24, 2025

Cidara Therapeutics to Report First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Cidara Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

Apr 24, 2025
pulisher
Apr 20, 2025

(CDTX) Trading Signals - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 16, 2025

Cidara Therapeutics (NASDAQ:CDTX) Upgraded to “Sell” at StockNews.com - Defense World

Apr 16, 2025
pulisher
Apr 12, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Apr 12, 2025
pulisher
Apr 07, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Cidara Therapeutics (NASDAQ:CDTX) Upgraded by StockNews.com to Sell Rating - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 25, 2025

(CDTX) Investment Analysis - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 21, 2025

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - MSN

Mar 21, 2025
pulisher
Mar 19, 2025

Cidara Therapeutics to Participate in World Health - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan

Mar 17, 2025
pulisher
Mar 16, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

(CDTX) Long Term Investment Analysis - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Mar 10, 2025

Cidara Therapeutics Inc Stock (CDTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):